Moderna starts Phase 1 trial for mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus

Moderna has begun a Phase 1 clinical trial of mRNA-1469, an investigational vaccine intended to protect against Bundibugyo ebolavirus, the company said in connection with a newly initiated early-stage study.

Phase 1 trials are the first step in human testing for an experimental medicine. At this stage, the primary focus is typically whether the product appears safe and whether it can generate a measurable immune response, rather than proving efficacy against infection.

According to the report, Moderna’s Phase 1 program for mRNA-1469 is being conducted in Canada. The company said it will evaluate safety and immune response, targeting a strain of Ebola virus disease for which no licensed vaccines are indicated, highlighting the need it sees for additional options in rare or underserved outbreaks.

The candidate is part of Moderna’s broader work using messenger RNA, or mRNA, technology, where genetic instructions delivered in a vaccine are designed to prompt the body to produce viral proteins and train the immune system. In early clinical research, regulators and companies generally look for immune markers that suggest the approach is working as intended.

The report also referenced an expanded collaboration in which the trial is being carried out. Moderna did not provide, in the available posting, additional operational details such as trial leadership, timelines, or the scope of the collaboration, beyond indicating it is part of a wider effort.

Moderna’s move comes as vaccine developers continue to test whether mRNA platforms can be rapidly adapted to different viral threats, including pathogens that are less common but can still cause severe outbreaks. For companies like Moderna, the ability to pursue multiple candidates across infectious diseases is also a way to diversify clinical pipelines beyond its core respiratory and oncology focus.

Still, the market implications of this announcement depend heavily on outcomes that are not yet disclosed. The available report does not specify expected enrollment, dosing regimen, study endpoints in detail, or any interim readouts for the trial, all of which will determine how quickly investors and clinicians can judge the program’s prospects.

What to watch next is whether Moderna will publish additional trial information, including the number of participants, dosing schedule, and immune-response data as the study progresses, and whether it can translate early safety and immunogenicity indicates into larger studies.